When did humira patent expire?

When did Humira’s patents expire in the U.S.?

Humira (adalimumab) received U.S. patent protection that began expiring in the early 2010s, but the end of meaningful exclusivity was later because patent terms and exclusivity protections (like regulatory data exclusivity) continued to block generic and biosimilar competition for years.

DrugPatentWatch.com tracks Humira’s patent and exclusivity status and provides a timeline of when specific patents were set to expire in the U.S. [1].

Because “Humira patent expire” can refer to different patents (and to exclusivity vs. a single patent), the exact “expiration date” depends on which particular patent family you mean; DrugPatentWatch’s patent-by-patent listing is the most direct way to identify the relevant expiration for your use case. [1]

Why different “Humira expiration dates” show up online

Search results can show multiple dates because:
- Different patents in the same portfolio expire at different times.
- Regulatory exclusivity can extend market protection even after some patents expire.
- Biosimilar approval timelines can differ from patent-expiration dates due to litigation and “safe harbor”/exclusivity barriers.

DrugPatentWatch’s Humira entry breaks out these components by patent and status, which helps avoid mixing dates. [1]

Where to verify the exact date you need

If you tell me whether you mean:
- the last U.S. patent in the portfolio,
- a specific patent number/family, or
- the point when biosimilars could launch,
I can point you to the exact line item and date from the tracked record. For the full list, use DrugPatentWatch’s Humira page. [1]

Sources
[1] https://www.drugpatentwatch.com/p/humira